Literature DB >> 15918796

Characterization of a novel, cytokine-inducible carboxypeptidase D isoform in haematopoietic tumour cells.

Padraic G P O'Malley1, Shirley M Sangster, Salma A Abdelmagid, Stephen L Bearne, Catherine K L Too.   

Abstract

CPD-N is a cytokine-inducible CPD (carboxypeptidase-D) isoform identified in rat Nb2 T-lymphoma cells. The prototypic CPD (180 kDa) has three CP domains, whereas CPD-N (160 kDa) has an incomplete N-terminal domain I but intact domains II and III. CPD processes polypeptides in the TGN (trans-Golgi network) but the Nb2 CPD-N is nuclear. The present study identified a cryptic exon 1', downstream of exon 1 of the rat CPD gene, as an alternative transcription start site that encodes the N-terminus of CPD-N. Western-blot analysis showed exclusive synthesis of the 160 kDa CPD-N in rat Nb2 and Nb2-Sp lymphoma cells. Several haematopoietic cell lines including human K562 myeloma, Jurkat T-lymphoma and murine CTLL-2 cytotoxic T-cells express a 160 kDa CPD-immunoreactive protein, whereas mEL4 T-lymphoma cells express the 180 kDa CPD. The CPD-immunoreactive protein in hK562 cells is also nuclear and cytokine-inducible. In contrast, MCF-7 breast cancer cells express only the 180 kDa CPD, which is mainly in the TGN. CPD/CPD-N assays using substrate dansyl-L-alanyl-L-arginine show approx. 98% of CPD-N activity in the Nb2 nucleus, whereas MCF-7 CPD activity is enriched in the post-nuclear 10000 g pellet. The K(m) for CPD-N and CPD are 132+/-30 and 63+/-9 microM respectively. Specific activity/K(m) ratios show that dansyl-L-alanyl-L-arginine is a better substrate for CPD-N than for CPD. CPD-N has an optimal pH of 5.6 (due to domain II), whereas CPD has activity peaks at pH 5.6 (domain II) and pH 6.5-7.0 (domain I). CPD and CPD-N are inhibited non-competitively by zinc chelator 1,10-phenanthroline and competitively by peptidomimetic inhibitor DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid. The Nb2 CPD-N co-immunoprecipitated with phosphatase PP2A (protein phosphatase 2A) and alpha4 phosphoprotein. In summary, a cytokine-inducible CPD-N is selectively expressed in several haematopoietic tumour cells. Nuclear CPD-N is enzymatically active and interacts with known partners of CPD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15918796      PMCID: PMC1199659          DOI: 10.1042/BJ20050025

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  The crystal structure of the inhibitor-complexed carboxypeptidase D domain II and the modeling of regulatory carboxypeptidases.

Authors:  P Aloy; V Companys; J Vendrell; F X Aviles; L D Fricker; M Coll; F X Gomis-Rüth
Journal:  J Biol Chem       Date:  2001-02-14       Impact factor: 5.157

2.  Carboxypeptidase D is up-regulated in raw 264.7 macrophages and stimulates nitric oxide synthesis by cells in arginine-free medium.

Authors:  V Hadkar; R A Skidgel
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  Sp1 is required for prolactin activation of the interferon regulatory factor-1 gene.

Authors:  M Book McAlexander; L Y Yu-Lee
Journal:  Mol Cell Endocrinol       Date:  2001-11-26       Impact factor: 4.102

4.  Prolactin, interleukin-2 and FGF-2 stimulate expression, nuclear distribution and DNA-binding of rat homolog of pombe Cdc5 in Nb2 T lymphoma cells.

Authors:  L M Johnson; C K Too
Journal:  Mol Cell Endocrinol       Date:  2001-11-26       Impact factor: 4.102

5.  Analysis of the carboxypeptidase D cytoplasmic domain: Implications in intracellular trafficking.

Authors:  Elena Kalinina; Oleg Varlamov; Lloyd D Fricker
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

6.  Sequences within the cytoplasmic domain of gp180/carboxypeptidase D mediate localization to the trans-Golgi network.

Authors:  F J Eng; O Varlamov; L D Fricker
Journal:  Mol Biol Cell       Date:  1999-01       Impact factor: 4.138

7.  Characterization of Drosophila carboxypeptidase D.

Authors:  Galyna Sidyelyeva; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2002-10-21       Impact factor: 5.157

8.  Implication of alpha4 phosphoprotein and the rapamycin-sensitive mammalian target-of-rapamycin pathway in prolactin receptor signalling.

Authors:  R T M Boudreau; S M Sangster; L M Johnson; S Dauphinee; A W Li; C K L Too
Journal:  J Endocrinol       Date:  2002-06       Impact factor: 4.286

9.  Protein phosphatase 2A binds to the cytoplasmic tail of carboxypeptidase D and regulates post-trans-Golgi network trafficking.

Authors:  O Varlamov; E Kalinina; F Y Che; L D Fricker
Journal:  J Cell Sci       Date:  2001-01       Impact factor: 5.285

10.  MID1 and MID2 homo- and heterodimerise to tether the rapamycin-sensitive PP2A regulatory subunit, alpha 4, to microtubules: implications for the clinical variability of X-linked Opitz GBBB syndrome and other developmental disorders.

Authors:  Kieran M Short; Blair Hopwood; Zou Yi; Timothy C Cox
Journal:  BMC Cell Biol       Date:  2002-01-04       Impact factor: 4.241

View more
  2 in total

1.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor.

Authors:  Daniel Fernández; Sebastian Testero; Josep Vendrell; Francesc X Avilés; Shahriar Mobashery
Journal:  Chem Biol Drug Des       Date:  2009-11-04       Impact factor: 2.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.